Natera, Inc.
NTRA Healthcare Diagnostics & Research
Natera, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 35.9% from fiscal 2024.
- Revenue
- +34.1%
- EPS
- +34.4%
- Free cash flow
- −85.8%
- Total debt
- −0.06%
Quarter to September 2026, against a year earlier
Follow NTRA
Alert me
Natera, Inc. (NTRA) P/B ratio
As of 5 November 2026, Natera, Inc. (NTRA) trades at a P/B ratio of 28.2×. Over the past ten years it has ranged from 0.0× (September 2018) to 348× (June 2019); the current reading is higher than 91% of that period. That is above the Diagnostics & Research industry median of 3.4× and above the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 18.3× | 10.75% |
| FY2024 | 16.5× | 77.51% |
| FY2023 | 9.3× | 73.36% |
| FY2022 | 5.4× | (58.54%) |
| FY2021 | 12.9× | (21.93%) |
| FY2020 | 16.6× | 97.21% |
| FY2019 | 8.4× | (66.52%) |
| FY2018 | 25.1× | 26.41% |
| FY2017 | 19.9× | 244.88% |
| FY2016 | 5.8× | 276.01% |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Sep 2026 | 31.8× | 49.16% |
| Jun 2026 | 21.4× | 33.85% |
| Mar 2026 | 16.0× | (12.79%) |
| Dec 2025 | 18.3× | 3.72% |
| 43 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| WAT Waters Corporation compare | 2.9× |
| LH Labcorp Holdings Inc. compare | 3.3× |
| DGX Quest Diagnostics Incorporated compare | 3.5× |
| IQV IQVIA Holdings Inc. compare | 6.4× |
| A Agilent Technologies, Inc. compare | 6.6× |
| ILMN Illumina, Inc. compare | 10.1× |
| NTRA Natera, Inc. | 28.2× |
| IDXX IDEXX Laboratories, Inc. compare | 28.2× |
| MTD Mettler-Toledo International, Inc. compare | 2,631× |
| Diagnostics & Research industry median | 3.4× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on NTRA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement